Clinical Trials Logo

Relapsed Non Hodgkin Lymphoma clinical trials

View clinical trials related to Relapsed Non Hodgkin Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04150913 Active, not recruiting - Clinical trials for Non Hodgkin Lymphoma

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL). - Relapsed NHL is the condition of returned Non-Hodgkin lymphoma. - Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma. - Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash. - Neurologic toxicity is nervous system disorder characterized by confusion This research study involves two drugs: - Anakinra - Axicabtagene Ciloleucel.

NCT ID: NCT03778619 Active, not recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Start date: November 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.

NCT ID: NCT03505944 Active, not recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

VALERIA
Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

NCT ID: NCT01811368 Active, not recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Start date: March 12, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving rituximab, antithymocyte globulin, and TLI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Giving a radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.